Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.

Abstract

INTRODUCTION Primary factor VIII (FVIII) prophylaxis is the optimal treatment in children with severe haemophilia A. They are expected to benefit from extended half-life (T1/2 ) FVIII coverage by reduced infusion frequency while maintaining haemostatic efficacy. AIMS To determine immunogenicity, pharmacokinetics (PK), efficacy, safety and quality of life… (More)
DOI: 10.1111/hae.13119

Topics

7 Figures and Tables

Cite this paper

@article{Mullins2017ExtendedHP, title={Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.}, author={Eric S Mullins and Oleksandra Stasyshyn and Mar{\'i}a Teresa {\'A}lvarez-Rom{\'a}n and Deeqa Osman and Ri J Liesner and Werner Engl and Marlies Sharkhawy and Brigitt E Abbuehl}, journal={Haemophilia : the official journal of the World Federation of Hemophilia}, year={2017}, volume={23 2}, pages={238-246} }